LATE-BREAKING ABSTRACT: Anti-interleukin-5 in severe asthma: Blood eosinophilia predicts lung function improvement

S. Korn, T. Schiffer, R. Buhl (Mainz, Germany)

Source: Annual Congress 2013 –Origins and diagnosis of asthma
Session: Origins and diagnosis of asthma
Session type: Oral Presentation
Number: 5020
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Korn, T. Schiffer, R. Buhl (Mainz, Germany). LATE-BREAKING ABSTRACT: Anti-interleukin-5 in severe asthma: Blood eosinophilia predicts lung function improvement. Eur Respir J 2013; 42: Suppl. 57, 5020

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
LATE-BREAKING ABSTRACT: Reslizumab in patients with late-onset asthma with elevated blood eosinophils
Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment
Year: 2015

LATE-BREAKING ABSTRACT: Exacerbation phenotype directed corticosteroid therapy of COPD: Value of blood eosinophilia (primary results)
Source: International Congress 2015 – The relevance of diagnostic and monitoring tools in clinical practice
Year: 2015


LATE-BREAKING ABSTRACT: Disease control rate (DRC) of bronchial asthma during pregnancy
Source: Annual Congress 2013 –Diagnosis and management of respiratory diseases
Year: 2013


LATE-BREAKING ABSTRACT: Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study
Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment
Year: 2014

LATE-BREAKING ABSTRACT: Benralizumab reduces exacerbations in severe, uncontrolled asthma: Results of the phase III CALIMA trial
Source: International Congress 2016 – Late-breaking topics in airways disease
Year: 2016



LATE-BREAKING ABSTRACT: Benralizumab for mild to moderate, persistent asthma: The BISE phase III study
Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives
Year: 2016



LATE-BREAKING ABSTRACT: Vocal cord dysfunction (VCD) in mild and severe asthma
Source: International Congress 2016 – Features and impact of comorbidities in COPD
Year: 2016


LATE-BREAKING ABSTRACT: The analysis of the severe asthma prevalence rate in China
Source: International Congress 2016 – Prevalence of obstructive airway diseases, methods of diagnosis, and lung function testing
Year: 2016


Comparison of clinical features of severe persistent asthma and refractory asthma
Source: Annual Congress 2013 –Phenotyping asthma: clinical severity, comorbid conditions response to treatment?
Year: 2013


Characterisation of asthma patients with persistent airflow obstruction
Source: International Congress 2016 – Clinical studies in asthma and immunology
Year: 2016


Clinical outcomes in non-eosinophilic versus eosinophilic asthma after 12 months specialist management
Source: International Congress 2015 – Non-exhaled biomarkers in the assessment of airways disease
Year: 2015

LATE-BREAKING ABSTRACT: Benralizumab provides significant improvements for patients with severe, uncontrolled asthma: SIROCCO Phase III results
Source: International Congress 2016 – Novel strategies on COPD and asthma management
Year: 2016


Usefulness of induced sputum eosinophil count to assess severity and treatment outcome in asthma patients
Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases
Year: 2013


Prevalence of refractory asthma in population with severe asthma
Source: International Congress 2016 – Phenotyping and monitoring airway diseases
Year: 2016


LATE-BREAKING ABSTRACT: A phase 2 study of benralizumab on exacerbations, lung function, and asthma control in adults with uncontrolled eosinophilic asthma
Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment
Year: 2014


Effects of beta-blockers on lung function in bronchial asthma patients
Source: International Congress 2014 – Asthma or COPD: comorbid condition or a poorly understood single disease?
Year: 2014

Clinical-functional and inflammatory evolution after one year of tracking in patients with asthma according to induced sputum cellularity
Source: International Congress 2015 – Immune mechanisms in the human lung
Year: 2015


Blood eosinophils, exacerbations in the previous year, lung function and ICS dose predict frequent exacerbations in asthma
Source: International Congress 2016 – Phenotyping asthma
Year: 2016


Asthma control, symptoms and exacerbations across treatment levels in patients with asthma
Source: Annual Congress 2013 –Management of respiratory diseases in primary care
Year: 2013


LATE-BREAKING ABSTRACT: Oral corticosteroid-sparing effect of mepolizumab in severe eosinophilic asthma: the SIRIUS study
Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment
Year: 2014